Piper Sandler experts have reduced the price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $1,013.00.

2 min read | January 28, 2025 12:29 AM PST | By Team Kalkine Media

Piper Sandler experts have reduced the price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $1,013.00.

Regeneron Pharmaceuticals’ Recent Market Movements

Regeneron Pharmaceuticals (NASDAQ:REGN) has recently seen adjustments in its stock price target by leading financial entities. Piper Sandler, a notable Wall Street research firm, revised its price target on Regeneron from $1,195.00 to $1,013.00.

Expert Ratings and Stock Performance

Across the board, several other experts have also shared their perspectives on Regeneron’s stock. Truist Financial, Barclays, and Evercore ISI are among those who have tapered their price targets, setting figures at $1,004.00, $1,065.00, and $1,175.00 respectively. Notably, BMO Capital Markets adjusted its target from $1,300.00 down to $1,190.00. Cantor Fitzgerald holds a neutral stance with a price objective of $1,015.00.

Stock Trends and Institutional Engagement

Regeneron Pharmaceuticals opened trading at $684.71, nestled between its 52-week low of $666.25 and high of $1,211.20. With a market capitalization standing robust at $75.24 billion, the company is noted for its P/E ratio of 16.94 and a P/E/G ratio of 1.59. The financial stability of the company is further exemplified through its quick ratio of 4.46, a current ratio of 5.28, and a minimal debt-to-equity ratio of 0.09. The business's stock trajectory is outlined by a 50-day moving average of $727.19 and a 200-day average of $936.01.

Institutional Investment Insights

Significant activity is observed in institutional management with entities like Adirondack Trust Co. and UMB Bank n.a., marking incremental upticks in their holdings. Strategic adjustments are also noted in Trust Co. of Vermont and Nvwm LLC, with Moss Adams Wealth Advisors LLC expanding their shares, reflecting pervading institutional confidence.

At present, institutional investors and hedge funds collectively own approximately 83.31% of Regeneron’s stock, presenting a strong backbone of support and positioning.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is globally recognized for its contributions to the discovery and commercialization of medicines aimed at treating a spectrum of diseases. Their notable product, EYLEA injection, addresses conditions such as wet age-related macular degeneration and diabetic macular edema, among other ocular ailments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.